PURE Bioscience (PK:PURE)

Business Focus: Household Products

Sector:  Consumer Non-Cyclicals Industry:  Household Products
See Regulatory Filings on SEC
Company Contact
Address: 1725 GILLESPIE WAY
EL CAJON CA 92020-1015
Tel: 1-619-5968600
Website: https://www.purebio.com
IR: See website
Key People
Tom Y. Lee
Chairman of the Board
Henry R. Lambert
Chief Executive Officer, Director
Mark Stuart Elliott
Chief Financial Officer, Chief Accounting Officer, Vice President - Finance
Tom Myers
Chief Operating Officer
Business Overview
PURE Bioscience, Inc. is focused on developing and commercializing antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control. The Company's technology platform is based on stabilized ionic silver and its products contain silver dihydrogen citrate (SDC). It offers PURE Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains and food processors. It is testing and continuing development of PURE Control to utilize PURE Control as a direct food contact processing aid for raw meats, including beef and pork. In addition to PURE Hard Surface and PURE Control, it manufactures and sells SDC-based products for end use; products preserved with SDC, and SDC as a raw material ingredient for manufacturing use. These products include PURE Multi-Purpose and Floor Cleaner Concentrate, PURE Multi-Purpose Hi-Foam Cleaner Concentrate, Axen 30, Axenohl and SILVERION.
Financial Overview
For the six months ended 31 January 2019, PURE Bioscience revenues increased 12% to $984K. Net loss decreased 12% to $3.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Inducement to exercise warrants decrease from $876K (expense) to $0K, Selling, general and administrative decrease of 26% to $2.1M (expense).
Employees: 11 as of Jul 31, 2015
Reporting Currency: U.S. Dollars
Enterprise value: $33.39M as of Jan 31, 2019
Annual revenue (TTM): $1.88M as of Jan 31, 2019
EBITDA (TTM): -$6.66M as of Jan 31, 2019
Net annual income (TTM): -$6.94M as of Jan 31, 2019
Free cash flow (TTM): -$3.29M as of Jan 31, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 74,113,371 as of Mar 6, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization